Diagnostic and Therapeutic Differences Between Immune Checkpoint Inhibitor-Induced and Idiopathic Bullous Pemphigoid: A Cross-Sectional Study.

Diagnostic and Therapeutic Differences Between Immune Checkpoint Inhibitor-Induced and Idiopathic Bullous Pemphigoid: A Cross-Sectional Study. Br J Dermatol. 2020 Jun 12;: Authors: Molina GE, Reynolds KL, Chen ST Abstract Bullous pemphigoid (BP) is a serious, rare complication from immune checkpoint inhibitors (ICIs). While most dermatologic immune-related adverse events (irAEs) present early and are mild, ICI-induced BP (ICI-BP) manifests months into therapy and can prompt ICI discontinuation and severe immunosuppression. Following irAE management guidelines, providers rely on systemic corticosteroids - which, at high doses, may confer poorer oncologic outcomes for ICI patients. Our study aims to identify diagnostic and therapeutic differences between ICI-BP and idiopathic BP (iBP) to assist providers in prompt recognition and management of this skin toxicity. PMID: 32531797 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research